{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:32:56Z","timestamp":1767335576537,"version":"3.48.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Overactivation of the complement system can cause life-threatening intravascular hemolysis, acute kidney injury (AKI), and multi-organ failure. Expanding the spectrum of rarer triggers of complement dysregulation that may cause severe hemolysis is essential for timely diagnosis and treatment. We report the case of a three-year-old boy admitted with macroscopic hematuria and jaundice. The patient tested positive for\n                    <jats:italic>Bordetella parapertussis<\/jats:italic>\n                    . Atypical hemolytic uremic syndrome (aHUS) was initially suspected due to decreasing hemoglobin, platelet count, and worsening of AKI, and empirical treatment with eculizumab (ECZ) was initiated. No red blood cell (RBC) autoantibodies were detected by standard serology methods or extended flow cytometry including antibody fixation at both room temperature and 4\u00b0C, no underlying hematological disorder was found, and genetic screening revealed no pathogenic variants associated with aHUS. However, the patient was strongly positive for C3 nephritic factor (C3NeF), an autoantibody stabilizing the C3 convertase (C3bBb) of the alternative complement pathway. C3NeF is typically linked to C3 glomerulopathy, but in this case appears to have triggered severe complement overdrive and extra- and intravascular hemolysis (bystander hemolysis) during an infection (two-hit immunopathology). Concomitantly,\n                    <jats:italic>B. parapertussis<\/jats:italic>\n                    is known to bind complement factor H, a key regulator of the alternative pathway, creating a \u201cperfect storm\u201d of dysregulation. Following infection control and complement blockade with ECZ, C3d deposition on RBCs declined, renal function recovered, and no clinical relapse has been observed 2 years and 6 months after discharge. To our knowledge, this is the first reported case of a possible C3NeF-driven complement-mediated severe hemolysis with associated AKI due to free hemoglobin toxicity during a severe infection.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1715464","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:28:15Z","timestamp":1767335295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Possible C3 nephritic factor\u2013driven complement-mediated severe hemolytic anemia and acute kidney injury in a child with Bordetella parapertussis infection"],"prefix":"10.3389","volume":"16","author":[{"given":"Steffen Ullitz","family":"Thorsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Todsen","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Jakob","family":"Hartling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne Vibeke","family":"Marquart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line","family":"Borgwardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira Marie","family":"Laustsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillemor","family":"Skattum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Christian Yde","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Line Thousig","family":"Sehested","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten Hanefeld","family":"Dziegiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Maria","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00926-1","article-title":"& Lambris, J. D. A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00281-021-00859-8","article-title":"Halting targeted and collateral damage to red blood cells by the complement system","volume":"43","author":"Jalink","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112257","article-title":"An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome","volume":"14","author":"Gastoldi","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00886","article-title":"Nephritic factors: an overview of classification, diagnostic tools and clinical associations","volume":"10","author":"Corvillo","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.02.018","article-title":"C3 nephritic factors: A changing landscape","volume":"140","author":"Levy Erez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2348662","article-title":"What is the role of complement in bystander hemolysis? Old concept, new insights","volume":"17","author":"Evangelidis","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13172","article-title":"The complement alternative pathway in health and disease\u2014activation or amplification","volume":"313","author":"Harrison","year":"2023","journal-title":"Immunol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00066-22","article-title":"Multicenter evaluation of the bioFire respiratory panel 2.1 (RP2.1) for detection of SARS-coV-2 in nasopharyngeal swab samples","volume":"60","author":"Berry","year":"2022","journal-title":"J Clin Microbiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02130.x","article-title":"Clinical application of a flow cytometric direct antiglobulin test","volume":"49","author":"Lin","year":"2009","journal-title":"Transfusion (Paris)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/archdischild-2020-319568","article-title":"How to use Donath-Landsteiner test to diagnose paroxysmal cold haemoglobinuria (PCH)","volume":"107","author":"Williams","year":"2022","journal-title":"Arch Dis Child. - Educ Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"20543581211008707","DOI":"10.1177\/20543581211008707","article-title":"Making the correct diagnosis in thrombotic microangiopathy: A narrative review","volume":"8","author":"McFarlane","year":"2021","journal-title":"Can J Kidney Health Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"a011742","DOI":"10.1101\/cshperspect.a011742","article-title":"Clinical manifestations of \u03b1-thalassemia","volume":"3","author":"Vichinsky","year":"2013","journal-title":"Cold Spring Harb. Perspect Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360843","article-title":"Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections","volume":"15","author":"Sejdic","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(82)90386-6","article-title":"A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes","volume":"51","author":"Rother","year":"1982","journal-title":"J Immunol Methods"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8949-2_13","article-title":"Analysis of C3 nephritic factors by ELISA","volume":"1901","author":"Skattum","year":"2019","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0290-5","article-title":"Testing the activity of complement convertases in serum\/plasma for diagnosis of C4NeF-mediated C3 glomerulonephritis","volume":"36","author":"Blom","year":"2016","journal-title":"J Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1036136","article-title":"Challenges in diagnostic testing of nephritic factors","volume":"13","author":"Michels","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u2018Kidney Disease: Improving Global Outcomes\u2019 (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006931","article-title":"Familial risk of developing atypical hemolytic-uremic syndrome","volume":"136","author":"Arjona","year":"2020","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.11.016","article-title":"Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA","volume":"296","author":"Seelen","year":"2005","journal-title":"J Immunol Methods"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015596","article-title":"Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics","volume":"140","author":"Vallelian","year":"2022","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.semnephrol.2020.01.006","article-title":"The role of circulating cell-free hemoglobin in sepsis-associated acute kidney injury","volume":"40","author":"Kerchberger","year":"2020","journal-title":"Semin Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901876","article-title":"Heme interferes with complement factor I-dependent regulation by enhancing alternative pathway activation","volume":"13","author":"Gerogianni","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40070801.x","article-title":"RBC T activation and hemolysis: implications for pediatric transfusion management","volume":"40","author":"Crookston","year":"2000","journal-title":"Transfusion (Paris)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.663258","article-title":"Eculizumab as a new treatment for severe acute post-infectious glomerulonephritis: two case reports","volume":"8","author":"Chehade","year":"2021","journal-title":"Front Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06373-x","article-title":"Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange","volume":"39","author":"Ferri","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"382463","DOI":"10.1155\/2015\/382463","article-title":"Activated complement factors as disease markers for sepsis","volume":"2015","author":"Charchaflieh","year":"2015","journal-title":"Dis Markers"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.62347\/HSVN8159","article-title":"Complement activation and humoral immune dysregulation drive progression of pediatric septic shock: a retrospective cohort study","volume":"17","author":"Xu","year":"2025","journal-title":"Am J Transl Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000520496","article-title":"Increase in the complement activation product C4d and the terminal complement complex sC5b-9 is associated with disease severity and a fatal outcome in necrotizing soft-tissue infection","volume":"14","author":"Hedetoft","year":"2021","journal-title":"J Innate Immun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.molimm.2010.11.015","article-title":"Interactions between Bordetella pertussis and the complement inhibitor factor H","volume":"48","author":"Amdahl","year":"2011","journal-title":"Mol Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01460","article-title":"Properdin is a key player in lysis of red blood cells and complement activation on endothelial cells in hemolytic anemias caused by complement dysregulation","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12166","article-title":"Storage of RBCs results in an increased susceptibility for complement-mediated degradation","volume":"24","author":"Kamhieh-Milz","year":"2014","journal-title":"Transfus. Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4103\/1110-1067.198654","article-title":"Leukoreduced red blood cell: storage-related complement regulatory proteins and CD47","volume":"41","author":"Farahat","year":"2016","journal-title":"Egypt. J Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1715464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:28:16Z","timestamp":1767335296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1715464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1715464"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1715464","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1715464"}}